Clinical Trial Update: A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating post-discharge Pradax for 10 days after total knee replacement was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboembolism

Drugs mentioned

• Pradax

Snippet

Sponsor: Ross Leighton | Conditions: Thromboembolism | Phase 4 | Status: WITHDRAWN